Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Oxy-PICU Neuroutvecklingsuppföljningsstudie (Oxy-PICU ND)

Background to the research: Each year around 20,000 children are admitted to paediatric intensive care units (PICUs) in the UK. Of these children, ~75% will receive support from a breathing machine (or ventilator) in combination with additional oxygen. The investigators recently completed the NIHR funded Oxy-PICU randomised clinical trial (RCT) - a study that compares one treatment against another to determine which is best. The Oxy-PICU RCT investigated whether children in PICU who are receiving help from a ventilator with additional oxygen, should have their oxygen levels kept at a lower level or higher level which currently used in the NHS. The investigators found that aiming for lower oxygen levels was better and resulted in a small but significant reduction in the number of days children spent on machines or died at 30 days.

While small, this result would have a large and important impact for patients and their families and may have important cost savings for the NHS. However, while in the short-term targeting lower oxygen levels appears better, the effects on children's longer-term development are unknown. Knowing this is important to fully inform doctors and nurses about the effects of aiming for lower oxygen levels, and help the results of Oxy-PICU be applied throughout the NHS.

Aim of the research: This research aims to complete longer-term follow-up of children included in the Oxy-PICU RCT. The study will look at the effect of aiming for lower oxygen levels compared to higher oxygen levels on longer-term developmental milestones.

Research plan: 1,112 parents of children included in the Oxy-PICU RCT will be invited by email and post to take part. A telephone interview will be arranged with the parent(s) who agree to participate. A trained researcher will use standard questionnaires to measure important issues. They'll establish if the children are meeting their developmental milestones and learn about their health related quality of life. After the interview a report will be sent to the parents detailing their child's development. It is anticipated that 50% of those approached will agree to take part in this study. This will allow important differences in developmental milestones to be detected in children treated with lower oxygen levels.

Patient and public involvement: PPI has been essential throughout Oxy-PICU. Our PPI co-applicant has been involved in Oxy-PICU from the start as a key member of the study team and will continue to help oversee all aspects of this research. A parent advisory group will be appointed to provide additional PPI input into the study processes.

Knowledge mobilisation: Outputs from the neurodevelopmental follow-up will be specifically targeted to the key stakeholders including patients/parents, clinicians and policy makers. Outputs for patients/parents and the public will be co-produced with our PPI representatives.

Studieöversikt

Status

Anmälan via inbjudan

Detaljerad beskrivning

Research question: In invasively ventilated critically ill children referred as an emergency for paediatric intensive care receiving supplementary oxygen [Population] what are the effects of a conservative oxygen therapy [Intervention] compared with a liberal oxygen therapy [Comparator] on longer-term neurodevelopmental function [Outcome]?

Background: The investigators recently completed the NIHR funded Oxy-PICU randomised clinical trial (RCT) which compared conservative versus liberal oxygenation targets in emergency admissions to PICU receiving invasive mechanical ventilation. The results showed a small but significant reduction in the number of days spent receiving organ support or death by day 30 with conservative oxygenation. While the effect size, in terms of the primary outcome, may appear small, if true, these results are clinically important to patients/parents and the NHS. While conservative oxygenation appears effective in the short term, questions still remain about the effects of targeting lower oxygen saturations on longer-term neurodevelopmental function, with calls made from PICU clinicians for this to be investigated prior to wider spread adoption of the Oxy-PICU trial results.

Aim: to extend and undertake additional follow-up of children enrolled in the Oxy-PICU RCT, to determine the effects of conservative oxygen therapy on longer-term neurodevelopmental function in critically ill children.

Methods: 1,112 parents of children included in the Oxy-PICU RCT will be invited by email and post to take part in this longer-term follow-up study. After agreeing to participate, a telephone interview will be arranged with the parent(s) consisting of two validated questionnaires: 1. Vineland Behaviour Scales, third edition (VABS-3) and 2. PedsQL™ 4.0 (Pediatric Quality of Life Inventory) which provide a validated proxy for neurodevelopmental functioning and quality of life, respectively. Once the interview has been completed, a report will be provided to the parents detailing their child's development.

Primary outcome: neurodevelopmental function defined as the overall adaptive behaviour VABS-3 score.

Sample size: Anticipating 50% of those approached agreeing to take part in this study, 556 parents completing telephone interviews will provide enough people to detect a clinically important difference in neurological and developmental function in children treated with conservative oxygen saturations compared with higher oxygen saturations.

Timeline: Total duration: 24 months: months 1-3: HRA approval and interview training; months 4-21: patient/parent recruitment and telephone interviews; months 22-24: analysis and dissemination.

Impact and dissemination: This research will have a large and immediate impact on patients, parents/guardians and the NHS. Understanding the neurodevelopmental effects of conservative oxygen therapy is imperative for implementation of the Oxy-PICU results, which has the potential for important clinical benefit for critically ill children and the NHS. The results will be actively disseminated with specific outputs targeted at patients and the public, PICU clinicians/researchers and policy makers. Outputs targeting patients and public will be co-designed with PPI representatives.

Studietyp

Observationell

Inskrivning (Beräknad)

556

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • London, Storbritannien, WC1V 6AZ
        • Intensive Care National Audit and Research Centre

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Barn
  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Parents/caregivers of children enrolled into Oxy-PICU and who provided consent to be contacted about future related research.

Beskrivning

Inclusion Criteria:

  1. Parent or caregiver of child included in the Oxy-PICU RCT;
  2. Provided consent to be contacted about future research;
  3. Living with child; and
  4. Child/young person survival status confirmed.

Exclusion Criteria:

None.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: FAMILY_BASED
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Conservative oxygenation

Patients that have previously received treatment in paediatric intensive care with conservative oxygenation

Liberal oxygenation

Patients that have previously received treatment in paediatric intensive care with liberal oxygenation

Patients that were previously randomised to receive conservative oxygenation while in paediatric intensive care

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Neurodevelopmental function defined as the overall adaptive behaviour score assessed using the Vineland Adaptive Behaviour Scales, third edition (VABS-3).
Tidsram: 4 years post randomization into the Oxy-PICU RCT (ISRCTN92103439)

Overall adaptive behaviour score obtained from the Vineland Adaptive Behaviour Scales, third edition (VABS-3) questionnaire.

4 years post randomization into the Oxy-PICU RCT (ISRCTN92103439)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
VABS-3 domain scores
Tidsram: 4 years post randomization into the Oxy-PICU RCT (ISRCTN92103439)

Individual VABS-3 domain scores (communication, daily living skills, socialisation, motor skills in younger children)

4 years post randomization into the Oxy-PICU RCT (ISRCTN92103439)
Health related quality of life
Tidsram: 4 years post randomization into the Oxy-PICU RCT (ISRCTN92103439)

Health related quality of life (HRQoL) measured using the Pediatric Quality of Life Inventory (PedsQL™) 4.0.

4 years post randomization into the Oxy-PICU RCT (ISRCTN92103439)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

23 juni 2025

Primärt slutförande (Beräknad)

1 mars 2027

Avslutad studie (Beräknad)

1 september 2027

Studieregistreringsdatum

Först inskickad

11 december 2024

Först inskickad som uppfyllde QC-kriterierna

11 december 2024

Första postat (Faktisk)

16 december 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

9 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

4 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • Oxy-PICU ND v1.0
  • NIHR206910 (Annat bidrag/finansieringsnummer: National Institute for Health and Care Research (NIHR) Research for Patient Benefit (RfPB))

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera